Pamidronic acid

DB00282ApprovedInvestigationalSmall moleculeBisphosphonatesBone Density Conservation Agents

Pamidronic acid is a bisphosphonate used to treat Paget's disease, to treat hypercalcemia of malignancy, and to treat osteolytic bone lesions. Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid.

Chemical structure of Pamidronic acid
Mechanism
Curator reviewed · 15 references
Primary indication
Pamidronate is indicated to treat moderate to severe hypercalcemia of malignancy, moderate to severe Paget's disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma.Curator reviewed · 4 structured indications
Formula / weight
C3H11NO7P2 · 235.0695 g/mol (avg)
First approval
Canada, 1997 · United States, 1991
Also known as
Pamidronate
Brand names
  • Pamisol

Resolves to

Structure
InChIKeyWRUUGTRCQOWXEG-UHFFFAOYSA-NSMILESNCCC(O)(P(O)(O)=O)P(O)(O)=O

What you can answer from here — as of September 23, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
885Drug interactionsStructured to mechanism, not free text
Sign in
35Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
157Marketed productsAcross 8 countries and 38 labellers
Sign in
1ATC codeIncluding every combination product, plus 11 drug categories
Sign in
32+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Pamidronic acid, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account